What is Oruka Therapeutics, Inc.'s (ORKA) StockRank?

MoatMap's StockRank for Oruka Therapeutics, Inc. (ORKA) is 27/100, with a Sell signal. This is a composite score combining Quality (36), Value (26), and Momentum (54) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Oruka Therapeutics, Inc. have an economic moat?

Oruka Therapeutics, Inc. (ORKA) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Oruka Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Oruka Therapeutics, Inc. (ORKA) is Sell, based on a StockRank of 27/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Oruka Therapeutics, Inc. in?

Oruka Therapeutics, Inc. (ORKA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ORKA

SellHot Air

Oruka Therapeutics, Inc. · Healthcare · United States · $6.0B · Avg Vol: $73M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-18.2%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutic candidates to address specific diseases with significant unmet medical needs. The company's potential competitive advantage will be derived from the efficacy and safety of its proprietary pipeline assets as they advance through clinical development.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM	2026E	2027E	Fwd CAGR
Revenue	—	0	—	—	—	—
EPS	—	-1.85	-2.04	-2.37	-2.86	—
Shares	37.4M	48.7M	—	—	—	—
Debt	1.0M	1.9M	2.5M	—	—	—
Equity	379.3M	469.0M	—	—	—	—
Op CF	—	-88.2M	-100.9M	—	—	—
Inv CF	—	-96.7M	—	—	—	—
Fin CF	—	170.3M	—	—	—	—

Loading 1Y...

PRICE (1Y)+6.4%

SMA 50SMA 200

$93.72

RSI (14)

24.9

52W High

$115.52

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-25.5%26.8

ROE

-18.2%30.9

GP/Assets

—N/A

Op. Margin

0.0%38.1

FCF/Assets

-18.7%22.0

Piotroski

14.0

Int. Cover

—N/A

D/E Ratio

0.00x91.9

Current Ratio

38.51x98.8

Value

P/E (TTM)

—N/A

EV/EBITDA

-33.9x25.0

P/FCF

—N/A

P/B

5.1x28.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

81%69.4

RS 6M

165%99.0

SMA 50/200

1.62x99.1

EPS Rev 4W

-14.8%6.4

EPS Rev 12W

-16.2%8.5

EPS Improve

-40%10.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$6.0B

P/E (Forward)

-32.3x

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ORKA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ORKA	Oruka Therapeutics, Inc.(you)	$6.0B	27	Sell
MIRM	Mirum Pharmaceuticals, Inc.	$5.9B	30	Sell
DNTH	Dianthus Therapeutics, Inc.	$5.9B	23	Sell
DFTX	Definium Therapeutics, Inc.	$5.5B	22	Sell
PTCT	PTC Therapeutics, Inc.	$5.8B	32	Sell
EWTX	Edgewise Therapeutics, Inc.	$4.6B	28	Sell
PCVX	Vaxcyte, Inc.	$8.9B	28	Sell
SYRE	Spyre Therapeutics, Inc.	$8.0B	23	Sell
RLAY	Relay Therapeutics, Inc.	$4.1B	28	Sell
RYTM	Rhythm Pharmaceuticals, Inc.	$7.4B	33	Sell

Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%

Oruka Therapeutics, Inc. (ORKA): Stock Score Summary

Oruka Therapeutics, Inc. (ORKA) has a MoatMap StockRank of 27/100 based on Quality (36/100), Value (26/100), and Momentum (54/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$93.72
Market Cap	$6.0B
P/E (Forward)	-32.32
Price/Book	5.08
Return on Equity	-18.2%
Return on Invested Capital	-25.5%
Debt/Equity	0.00x
Operating Margin	0.0%
Free Cash Flow	$-91M

Oruka Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Oruka Therapeutics, Inc.’s (ORKA) StockRank?: MoatMap’s StockRank for Oruka Therapeutics, Inc. (ORKA) is 27/100, with a Sell signal. It is a composite of Quality (36), Value (26), and Momentum (54) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Oruka Therapeutics, Inc. have an economic moat?: Oruka Therapeutics, Inc. (ORKA) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Oruka Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Oruka Therapeutics, Inc. (ORKA) is Sell, based on a StockRank of 27/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Oruka Therapeutics, Inc. in?: Oruka Therapeutics, Inc. (ORKA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).